Patents Assigned to Novartis
  • Amino pyrimidine derivatives
    Patent number: 11180460
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Licofligozin for the treatment of non-alcoholic steatohepatitis
    Patent number: 11179364
    Abstract: The disclosure concerns the use of LIK066 in the treatment, prevention or delay of non-alcoholic steatohepatitis.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Lloyd Klickstein, C. Daniel Meyers, Chinweike Ukomadu
  • Peptides and compositions for treatment of joint damage
    Patent number: 11179442
    Abstract: The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: November 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Kristen Johnson, Jian Shi
  • TGFbeta 2 antibodies
    Patent number: 11180546
    Abstract: This invention is in the field of anti-transforming growth factor beta 2 (TGF-?2) antibodies. In particular, the invention provides human monoclonal antibodies that bind the human TGF-?2 isoform preferentially over the human TGF-?1 or TGF-?3 isoforms.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Chikwendu Ibebunjo, Carsten Jacobi, Angelika Meyer, Eveline Schaadt, Anne-Ulrike Trendelenburg, Olga Vladimirovna Mitina
  • Expression vector system comprising two selection markers
    Patent number: 11174494
    Abstract: The invention pertains to an expression vector or a combination of at least two expression vectors comprising at least (a) a polynucleotide encoding a product of interest or an insertion site for incorporating a polynucleotide encoding a product of interest; (b) a polynucleotide encoding a first selectable marker (sm I); (c) a polynucleotide encoding a second selectable marker (sm II), which is different from the first selectable marker (sm I), wherein the activity of the selectable marker (sm I) or (sm II) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm I) and (sm II) are involved in the folate metabolism. Also provided are suitable host cells, selection methods and methods for producing polypeptides with high yield.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 16, 2021
    Assignee: Novartis AG
    Inventors: Thomas Jostock, Hans-Peter Knopf
  • Factor XI antibodies and methods of use
    Patent number: 11168147
    Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 9, 2021
    Assignee: NOVARTIS AG
    Inventors: Maximilian Aigner, Alexander Wolfgang Koch, Markus Waldhuber
  • Regimens and methods of treating multiple sclerosis using ofatumumab
    Patent number: 11161909
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • Pharmaceutical dosage forms
    Patent number: 11160804
    Abstract: The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 2, 2021
    Assignee: Novartis AG
    Inventor: Suzie Jesus Ribeiro
  • Car-expressing cells against multiple tumor antigens and uses thereof
    Patent number: 11161907
    Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 2, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Daniel J. Powell, Jr.
  • Pyridinone derivatives and their use as selective ALK-2 inhibitors
    Patent number: 11160797
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sylvie Chamoin, Pier Luca D'Alessandro, Mika Lindvall, Dimitrios Lizos, Nikolaus Johannes Stiefl, Sylvie Teixeira-Fouchard, Thomas Ullrich, Sven Weiler
  • Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
    Patent number: 11162065
    Abstract: The present disclosure relates to systems and methods for flow-through separation of paramagnetic particle-bound cells in a cell suspension containing both bound and unbound cells as well as systems and methods for removing paramagnetic particles from paramagnetic particle-bound cells or from a cell suspension with unbound cells. It further relates to a flow-through magnetic separation/debeading module and a flow-through spinning membrane debeading module.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 2, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Fabio Fachin, Rodney Rietze, Michael R. Greene, Lan Cao
  • Polyomavirus neutralizing antibodies
    Patent number: 11161894
    Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 2, 2021
    Assignee: Novartis AG
    Inventors: Johanna Abend, Zorica Dragic, Adam Lloyd Feire, Mark Knapp, Steven Kovacs, Elisabetta Traggiai, Lichun Wang, Yongqiang Wang, Danqing Wu, Qilong Wu, Fangmin Xu
  • Cell bag rotator
    Patent number: 11154827
    Abstract: A cell bag rotator is constructed to slowly agitate a plurality of cell bags by rotation along a rotation axis that is at least partially horizontal. The cell bag rotator comprises a plurality of plates to which a respective cell bag is attached. The cell bag rotator is suitable for mixing cells with particles for performing various types of subsequent cell therapy processes on the cells.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 26, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Thomas Callahan, Charles Duffy, Jr.
  • Method of detecting TIM-3 using antibody molecules to TIM-3
    Patent number: 11155620
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: October 26, 2021
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., The Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Syringe
    Patent number: 11147925
    Abstract: The invention provides a syringe for use in an ophthalmic injection. The syringe comprises a body, a stopper and a plunger. The body comprises an outlet at an outlet end and the stopper is arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled though the outlet. The plunger comprises a plunger contact surface at a first end and a rod extends between the plunger contact surface and a rear portion. The plunger contact surface is arranged to contact the stopper but not couple thereto, such that the plunger can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, but not to move the stopper away from the outlet end.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 19, 2021
    Assignee: NOVARTIS AG
    Inventors: Andrew Bryant, Heinrich Buettgen, Wolfgang Papst, Marie Picci
  • CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
    Patent number: 11149076
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 19, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Circulation of components during microfluidization and/or homogenization of emulsions
    Patent number: 11141376
    Abstract: An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: October 12, 2021
    Assignee: NOVARTIS AG
    Inventors: Harald Rueckl, Hanno Scheffczik, Barbara Santry
  • Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same
    Patent number: 11135239
    Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: October 5, 2021
    Assignee: NOVARTIS AG
    Inventors: Christoph Bucher, Dietmar Flubacher, Jeremiah Douglas Foutch, Malay Ghosh, Johannes Franz Kluge, Zaixing Li, Cale Ry McAlister, Liladhar Murlidhar Waykole, Jens Sören Worthmann, Tingying Zhu
  • Methods of treating immune related disorders using antibody-cytokine engrafted compositions
    Patent number: 11136366
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Inhibitors for treating diseases characterized by atrial enlargement or remodeling
    Patent number: 11135192
    Abstract: The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Christoph Schumacher, Thomas Holbro